×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: fda | drug | diabetes | heart failure | jardiance

FDA Approves Eli Lilly Drug to Cut Death, Hospitalization Risk in All Heart Patients

a heart and a hand holding a pill
(Dreamstime)

Thursday, 24 February 2022 04:05 PM EST

The U.S. health regulator said on Thursday it had approved Eli Lilly and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure.

Originally approved by the Food and Drug Administration in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure with reduced ejection fraction, which happens when the muscle of the left ventricle is not pumping as well as normal.

"While Jardiance may not be effective in all patients with heart failure, this approval is a significant step forward for patients and our understanding of heart failure," said Norman Stockbridge, director of the FDA's Division of Cardiology and Nephrology.

The expansion on Thursday now increases its market size to cover a very large patient population of about 6.2 million people, as per Centers for Disease Control and Prevention data.

Jardiance also faces competition from AstraZeneca Plc's drug Farxiga, which has approval for patients with symptomatic heart failure.

Eli Lilly recorded nearly $1.5 billion in revenue for Jardiance in 2021, while Farxiga garnered twice that amount for AstraZeneca. 

© 2022 Thomson/Reuters. All rights reserved.


Health-News
The U.S. health regulator said on Thursday it had approved Eli Lilly and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Originally approved by the Food and Drug...
fda, drug, diabetes, heart failure, jardiance
191
2022-05-24
Thursday, 24 February 2022 04:05 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved